Kelani has served as chairman and managing director since 2019. EIPICO operates five manufacturing facilities and owns 30% of Batterjee Pharma In H1 2025, the company reported a 36% year-on-year increase in revenues to $93 million. In June 2025, EIPICO announced it is in the final phase of completing its $100 million EIPICO 3 biopharmaceutical and biosimilar facility. In December 2024, he signed the land allocation contract for the $120 million Arab API factory in Ain Sokhna Economic Zone, jointly owned with EIPICO, ACDIMA, and the General Authority for Suez Canal Economic Zone.